Cite
HARVARD Citation
Rundquist, S. et al. (2021). Drug survival of anti‐TNF agents compared with vedolizumab as a second‐line biological treatment in inflammatory bowel disease: results from nationwide Swedish registers. Alimentary pharmacology & therapeutics. 53 (4), pp. 471-483. [Online].